Ellie’s Law
- Bill Number
- H.R. 2678
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-04-07: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-07-10T08:06:44Z
AI-Generated Summary
Purpose
This legislation aims to increase federal funding for research on unruptured intracranial aneurysms (bulging blood vessels in the brain that have not burst) at the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). It seeks to expand studies to include a more diverse group of patients by age, sex, and race, building on prior international research to improve understanding, prevention, and treatment of this condition.
Key Provisions
- Findings Section: Outlines the prevalence and impact of brain aneurysms, noting that about 6.8 million Americans (1 in 50) have unruptured ones, with 30,000 ruptures annually leading to 50% fatality and 66% of survivors facing permanent neurological damage (e.g., loss of brain function affecting movement or thinking). It highlights higher risks for women (3:2 ratio vs. men) and rupture rates for African Americans (2.1:1) and Hispanics (1.67:1) compared to Caucasians. Personal stories of five women who died from ruptures are included to humanize the issue. Economic costs are estimated at $2 billion annually in direct medical expenses (before insurance), with low federal research spending ($2.94 per affected person yearly). It references past International Study on Unruptured Intracranial Aneurysms (ISUIA) as foundational work.
- Funding Authorization: Allocates $20 million annually to NINDS for fiscal years 2026 through 2030 (totaling $100 million) for comprehensive research on unruptured aneurysms in diverse populations. Funds remain available until September 30, 2033.
- Supplement Requirement: New funds must add to, not replace, existing brain aneurysm research funding.
Significant Changes to Existing Law
- This bill introduces targeted, increased funding specifically for unruptured aneurysm research at NINDS, which was not previously authorized at this scale or with a focus on demographic diversity.
- It builds on existing NIH research frameworks but mandates supplementation of funds, ensuring no reduction in baseline aneurysm studies.
- No direct amendments to prior laws are specified, but it enhances the scope of neurological research under the Public Health Service Act (which governs NIH operations).
Potential Impacts
- Government Agencies: NINDS and NIH will receive dedicated resources to conduct or support broader studies, potentially accelerating clinical guidelines and treatments. This could strain administrative resources for grant management but overall bolsters federal health research capacity.
- Citizens: Improved research may lead to better early detection, risk assessment, and interventions, reducing deaths and disabilities from ruptures—especially benefiting women, African Americans, and Hispanics. Families of victims could see indirect support through awareness raised by the bill's personal stories. Economic burdens on patients (e.g., high ICU costs averaging $114,000 per case) might decrease long-term via preventive advances.
- International Relations: Minimal direct impact, though expanded U.S. research could contribute to global studies like ISUIA, fostering international collaboration on aneurysm management.
Main Stakeholders Affected
- Patients and Families: Individuals with or at risk for aneurysms (e.g., 6.8 million unruptured cases), particularly women and minorities; families of rupture victims, honored through the bill's namesakes.
- Healthcare Providers and Researchers: Doctors, neurologists, and scientists at NINDS/NIH who will access new funding for studies; hospitals facing high treatment costs.
- Advocacy Groups: Organizations supporting brain aneurysm awareness, potentially empowered by increased federal focus.
- Government Entities: Congress (via Energy and Commerce Committee oversight) and NIH, responsible for implementing and reporting on fund use.
- Broader Society: Taxpayers funding the research; underserved communities with higher rupture risks.
Notable Legal, Constitutional, or Political Implications
- Legal: Authorizes appropriations without mandating spending, giving Congress flexibility in budgeting (subject to annual appropriations process). Ensures research complies with NIH ethical standards for human studies, emphasizing diversity to address health disparities.
- Constitutional: Aligns with Congress's power to spend for the general welfare (Article I, Section 8), promoting public health without infringing on individual rights.
- Political: Honors specific victims to build bipartisan support (introduced by members from both parties), highlighting underfunded research amid rising healthcare costs. Could set precedent for naming laws after individuals to advance niche health issues, potentially influencing future NIH funding priorities without altering broader fiscal policies. No major controversies noted, as it focuses on non-partisan medical research.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Fitzpatrick, Brian K. [R-PA-1]
Cosponsors (54)
Rep. Clarke, Yvette D. [D-NY-9], Rep. Rutherford, John H. [R-FL-5], Rep. Scanlon, Mary Gay [D-PA-5], Rep. Houlahan, Chrissy [D-PA-6], Rep. Lynch, Stephen F. [D-MA-8], Rep. Tlaib, Rashida [D-MI-12], Rep. Bacon, Don [R-NE-2], Rep. Nadler, Jerrold [D-NY-12], Rep. Latimer, George [D-NY-16], Rep. DelBene, Suzan K. [D-WA-1], Rep. Gottheimer, Josh [D-NJ-5], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Casten, Sean [D-IL-6], Rep. Wilson, Joe [R-SC-2], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Trahan, Lori [D-MA-3], Rep. Lawler, Michael [R-NY-17], Rep. Craig, Angie [D-MN-2], Rep. Swalwell, Eric [D-CA-14], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Bresnahan, Robert P. [R-PA-8], Rep. Magaziner, Seth [D-RI-2], Rep. Davis, Donald G. [D-NC-1], Rep. Hayes, Jahana [D-CT-5], Rep. Sewell, Terri A. [D-AL-7], Rep. Moulton, Seth [D-MA-6], Rep. Thompson, Bennie G. [D-MS-2], Rep. Deluzio, Christopher R. [D-PA-17], Rep. Pressley, Ayanna [D-MA-7], Rep. Van Drew, Jefferson [R-NJ-2], Rep. Khanna, Ro [D-CA-17], Rep. Keating, William R. [D-MA-9], Rep. Raskin, Jamie [D-MD-8], Rep. Castor, Kathy [D-FL-14], Rep. Peters, Scott H. [D-CA-50], Rep. Hudson, Richard [R-NC-9], Rep. Pingree, Chellie [D-ME-1], Rep. Dean, Madeleine [D-PA-4], Rep. Ross, Deborah K. [D-NC-2], Rep. McGovern, James P. [D-MA-2], Rep. Neguse, Joe [D-CO-2], Rep. Boyle, Brendan F. [D-PA-2], Rep. Walkinshaw, James R. [D-VA-11], Rep. Pocan, Mark [D-WI-2], Rep. Kennedy, Timothy M. [D-NY-26], Rep. Pappas, Chris [D-NH-1], Rep. Carter, Troy A. [D-LA-2], Rep. Suozzi, Thomas R. [D-NY-3], Rep. Watson Coleman, Bonnie [D-NJ-12], Rep. Norcross, Donald [D-NJ-1] and 4 more
Recent Actions
- 2025-04-07: Referred to the House Committee on Energy and Commerce.
- 2025-04-07: Introduced in House
- 2025-04-07: Introduced in House
Bill Versions
- Ellie Helton, Lisa Colagrossi, Kristen Shafer Englert, Teresa Anne Lawrence, and Jennifer Sedney Focused Research Act — issued 2025-04-07 — PDF (6 pages)